Table 1. Analysis of plasmablast percentage after PBMC stimulation with Encepur vaccine and the different vaccine components.
| Experimental Conditions | Plasmablasts (%) | IgM+ Plasmablasts (%) | IgG/IgA+ Plasmablasts (%) |
|---|---|---|---|
| NS | 1.13 ± 0.32 | 47.25 ± 1.28 | 52.8 ± 1.23 |
| R848 5μM | 15.96 ± 6.49 | 26.75 ± 4.05 | 73.25 ± 4.05 |
| I-TBEV 1:12.5 | 9.98 ± 2.26* | 54 ± 1.43* | 45.99 ± 1.42* |
| ENCEPUR 1:12.5 | 4.02 ± 0.93* | 62.43 ± 2.80 | 37.56 ± 2.80 |
| EXCIPIENT 1:12.5 | 5.47 ± 2.89 | 41.72 ± 1.16 | 58.28 ± 1.16 |
| SUCROSE 1:12.5 | 3.07 ± 0.29* | 47.03 ± 3.33 | 52.97 ± 3.33 |
Peripheral blood mononuclear cells (PBMC) were stimulated with R848 (5μM), inactivated TBEV (I-TBEV), Encepur vaccine, excipient and sucrose (1:12.5) or left untreated (NS) for 10 days and the percentages of CD27hiCD38hi plasmablasts and IgM+ or IgG/IgA+ plasmablasts were measured by cytofluorimetric analysis. The results shown were mean relative values ± standard error of the mean of 5 independent experiments. ANOVA p value for plasmablast percentage: 0.018. ANOVA p value for IgM+ plasmablast percentage: 0.022. ANOVA p value for IgA/IgG+ plasmablast percentage: 0.031. Based on LSD (equivalent to no adjustments).